Advertisement

Cancer Immunology, Immunotherapy

, Volume 56, Issue 1, pp 70–80 | Cite as

The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines

  • Deepak P. Assudani
  • Roger B. V. Horton
  • Morgan G. Mathieu
  • Stephanie E. B. McArdle
  • Robert C. ReesEmail author
Symposium Paper

Abstract

Recent years have seen the unprecedented surge of interest in the role of CD4+ T cells and the role they play in the development of the immune response. In this symposium review, we examine the evidence for this and discuss their functions, particularly in respect to the cancer immunology, including CD4+CD25+ cells (Treg).

Keywords

Dendritic Cell Activation Induce Cell Death Restricted Peptide CT26 Tumour Cell Loaded Dendritic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Adam C, King S, Allgeier T, Braumuller H, Luking C, Mysliwietz J, Kriegeskorte A, Busch DH, Rocken M, Mocikat R (2005) DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 106:338–344CrossRefPubMedGoogle Scholar
  2. 2.
    Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844–854CrossRefPubMedGoogle Scholar
  3. 3.
    Ahmad M, Rees RC, McArdle SE, Li G, Mian S, Entwisle C, Loudon P, Ali SA (2005) Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC–mGM–CSF. Int J Cancer 115:951–959CrossRefPubMedGoogle Scholar
  4. 4.
    Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. Blood 107(6):2409–2414CrossRefPubMedGoogle Scholar
  5. 5.
    Ali SA, Lynam J, McLean CS, Entwisle C, Loudon P, Rojas JM, McArdle SE, Li G, Mian S, Rees RC (2002) Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. J Immunol 168:3512–3519PubMedGoogle Scholar
  6. 6.
    Ali SA, Ahmad M, Lynam J, McLean CS, Entwisle C, Loudon P, Choolun E, McArdle SE, Li G, Mian S, Rees RC (2004) Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 22:3585–3594CrossRefPubMedGoogle Scholar
  7. 7.
    Allan SE, Passerini L, Bachetta R, Crellin N, Dai M, Orban PC, Ziegler SF, Roncarolo MG, Levings MK (2005) The role of 2 Foxp3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 115(11):3276–3284CrossRefPubMedGoogle Scholar
  8. 8.
    Assudani DP, Ahmad M, Li G, Rees RC, Ali SA (2005) Immunotherapeutic potential of DISC–HSV and OX40L in cancer. Cancer Immunol Immunother 6:1–8Google Scholar
  9. 9.
    Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y (1999) TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 189:1025–1031CrossRefPubMedGoogle Scholar
  10. 10.
    Baecher-Allan C, Viglietta V, Haller DA (2004) Human CD4+CD25+ regulatory T cells. Semin Immunol 16:89–97CrossRefPubMedGoogle Scholar
  11. 11.
    Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478–480CrossRefPubMedGoogle Scholar
  12. 12.
    Bevan MJ (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4:595–602CrossRefPubMedGoogle Scholar
  13. 13.
    Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R (2003) Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 9:540–547CrossRefPubMedGoogle Scholar
  14. 14.
    Bourgeois C, Rocha B, Tanchot C (2002) A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297:2060–2063CrossRefPubMedGoogle Scholar
  15. 15.
    Buller RM, Holmes KL, Hugin A, Frederickson TN, Morse HC 3rd (1987) Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature 328:77–79CrossRefPubMedGoogle Scholar
  16. 16.
    Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent anti-angiogenic activity, as well as long-lasting tumour immunity elicited by peptide vaccination. J Immunol 171(11):5931–5939PubMedGoogle Scholar
  17. 17.
    Cassell D, Forman J (1988) Linked recognition of helper and cytotoxic antigenic determinants for the generation of cytotoxic T lymphocytes. Ann NY Acad Sci 532:51–60PubMedGoogle Scholar
  18. 18.
    Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T-cell response and tumour vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65:794–802CrossRefPubMedGoogle Scholar
  19. 19.
    Chang CC, Satwani P, Oberfield N, Vlad G, Simpson LL, Cairo MS (2005) Increased induction of allogeneic-specific cord blood CD4+CD25+ regulatory T (Treg) cells: a comparative study of naive and antigenic-specific cord blood Treg cells. Exp Hematol 33:1508–1520CrossRefPubMedGoogle Scholar
  20. 20.
    Chatila TA (2005) Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116:949–959CrossRefPubMedGoogle Scholar
  21. 21.
    Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3:37–44PubMedGoogle Scholar
  22. 22.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949CrossRefPubMedGoogle Scholar
  23. 23.
    Daniel D, Chiu C, Giraudo E, Inoue M, Mizzen LA, Chu NR, Hanahan D (2005) CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res 65:2018–2025CrossRefPubMedGoogle Scholar
  24. 24.
    Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115(12):3623–3633CrossRefPubMedGoogle Scholar
  25. 25.
    Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G (2002) Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 196:247–253CrossRefPubMedGoogle Scholar
  26. 26.
    Dranoff G (2003) GM–CSF-based cancer vaccines. Immunol Rev 188:147–154CrossRefGoogle Scholar
  27. 27.
    Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363–373CrossRefPubMedGoogle Scholar
  28. 28.
    Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25:243–251CrossRefPubMedGoogle Scholar
  29. 29.
    Echchakir H, Bagot M, Dorothee G, Martinvalet D, Le Gouvello S, Boumsell L, Chouaib S, Bensussan A, Mami-Chouaib F (2000) Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 115:74–80CrossRefPubMedGoogle Scholar
  30. 30.
    Egilmez NK, Hess SD, Chen FA, Takita H, Conway TF, Bankert RB (2002) Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 62:2611–2617PubMedGoogle Scholar
  31. 31.
    Franco A, Tilly DA, Gramaglia I, Croft M, Cipolla L, Meldal M, Grey HM (2000) Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat Immunol 1:145–150CrossRefPubMedGoogle Scholar
  32. 32.
    Fuller MJ, Hildeman DA, Sabbaj S, Gaddis DE, Tebo AE, Shang L, Goepfert PA, Zajac AJ (2005) Cutting edge: emergence of CD127high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J Immunol 174:5926–5930PubMedGoogle Scholar
  33. 33.
    Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJ (2002) Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 62:6438–6441PubMedGoogle Scholar
  34. 34.
    Germain RN, Castellino F, Chieppa M, Egen JG, Huang AY, Koo LY, Qi H (2005) An extended vision for dynamic high-resolution intravital immune imaging. Semin Immunol 17:431–441PubMedCrossRefGoogle Scholar
  35. 35.
    Godfrey DI, Kronenberg M (2004) Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379–1388CrossRefPubMedGoogle Scholar
  36. 36.
    Greenberg PD, Kern DE, Cheever MA (1985) Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2− T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 16:1122–1134CrossRefGoogle Scholar
  37. 37.
    Hogquist KA, Baldwin TA, Jameson SC (2005) Central tolerance: learning self-control in the thymus. Nat Rev Immunol 5:772–782CrossRefPubMedGoogle Scholar
  38. 38.
    Huang (2005) CRI symposiumGoogle Scholar
  39. 39.
    Huang AY, Qi H, Germain RN (2004) Illuminating the landscape of in vivo immunity: insights from dynamic in situ imaging of secondary lymphoid tissues. Immunity 21:331–339PubMedGoogle Scholar
  40. 40.
    Huehn J, Hamann A (2005) Homing to suppress: address codes for Treg migration. Trends Immunol 26:632–636CrossRefPubMedGoogle Scholar
  41. 41.
    Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fuji H (2003) Increased population of regulatory T cells in peripheral blood and tumour infiltrated lymphocytes in patients with gastric and oesophageal cancers. Clin Cancer Res 9:4404–4408PubMedGoogle Scholar
  42. 42.
    Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109CrossRefPubMedGoogle Scholar
  43. 43.
    Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, Griffith TS, Green DR, Schoenberger SP (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434:88–93CrossRefPubMedGoogle Scholar
  44. 44.
    Kawaida H, Kono K, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Ooi A, Fuji H (2005) Distribution of CD4(+)CD25high regulatory T cells in tumour-draining lymph nodes in patients with gastric cancer. J Surg Res 124(1):151–157CrossRefPubMedGoogle Scholar
  45. 45.
    Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54:721–728CrossRefPubMedGoogle Scholar
  46. 46.
    Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S (2005) Treatment of advanced tumours with agonistic anti-GITR mAb and its effects on tumour-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202:885–891CrossRefPubMedGoogle Scholar
  47. 47.
    Lopex-Dias de Cerio AL, Casares N, Lasarte JJ, Sarobe P, Perez-Mediavilla LA, Ruiz M, Prieto J, Borras-Cuesta F (1999) T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. Int Immunol 11:2025–2034CrossRefPubMedGoogle Scholar
  48. 48.
    Lu C, Sheehan C, Rak JW, Chambers CA, Hozumi N, Kerbel RS (1996) Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res 2:1417–1425PubMedGoogle Scholar
  49. 49.
    Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM (2000) CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med 191:541–550CrossRefPubMedGoogle Scholar
  50. 50.
    Lundin KU, Screpanti V, Omholt H, Hofgaard PO, Yagita H, Grandien A, Bogen B (2004) CD4+ T cells kill Id+ B-lymphoma cells: FasLigand–Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother 53:1135–1145CrossRefPubMedGoogle Scholar
  51. 51.
    Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F (2005) Thymic regulatory T cells. Autoimmun Rev 4:579–586CrossRefPubMedGoogle Scholar
  52. 52.
    Matoba K, Iizuka N, Gondo T, Ishihara T, Yamada-Okabe H, Tamesa T, Takemoto N, Hashimoto K, Sakamoto K, Miyamoto T, Uchimura S, Hamamoto Y, Oka M (2005) Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer 115:231–240CrossRefPubMedGoogle Scholar
  53. 53.
    Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I (2004) T cell repertoire scanning is promoted by dynamic dendritic cell behaviour and random T cell motility in the lymph node. Proc Natl Acad Sci USA 101:998–1003CrossRefPubMedGoogle Scholar
  54. 54.
    Moskophidis D, Lechner F, Pircher H, Zinkernagel RM (1993) Virus persistence in acutely infected immuno-competent mice by exhaustion of antiviral cytotoxic effector cells. Nature 362:758–761CrossRefPubMedGoogle Scholar
  55. 55.
    Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T-helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769–776CrossRefPubMedGoogle Scholar
  56. 56.
    Nishikawa H, Kato T, Tanida K, Hiasa A, Tawara I, Ikeda H, Ikarashi Y, Wakasugi H, Kronenberg M, Nakayama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H (2003) CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 100:10902–10906CrossRefPubMedGoogle Scholar
  57. 57.
    Nishikawa H, Kato T, Tawara I, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Old LJ, Shiku H (2005) IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 175:4433–4440PubMedGoogle Scholar
  58. 58.
    Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190:617–627CrossRefPubMedGoogle Scholar
  59. 59.
    Ohashi PH, Oehen K, Burki HP, Pircher T, Ohasi B, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H (1991) Ablation of “tolerance” and induction of diabetes by virus infection in virus antigen transgenic mice. Cell 65:305–317CrossRefPubMedGoogle Scholar
  60. 60.
    Orabona C, Grohmann U, Belladona ML, Fallarino F, Vacca C, Bianchi R, Bozza S, Volpi C, Salomon BL, Fioretti MC, Romani L, Pucceti P (2004) CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 5:1134–1142CrossRefPubMedGoogle Scholar
  61. 61.
    Parkinson RJ, Mian S, Bishop MC, Gray T, Li G, McArdle SE, Ali S, Rees RC (2003) Disabled infectious single cycle herpes simplex virus (DISC–HSV) is a candidate vector system for gene delivery/expression of GM–CSF in human prostate cancer therapy. Prostate 56:65–73CrossRefPubMedGoogle Scholar
  62. 62.
    Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA (2000) Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. J Immunol 165:5738–5749PubMedGoogle Scholar
  63. 63.
    Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF (2005) Toll-like receptor 8-mediated reversal of CD4+ regulatory T-cell function. Science 309:1380–1384CrossRefPubMedGoogle Scholar
  64. 64.
    Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377CrossRefPubMedGoogle Scholar
  65. 65.
    Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T-cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137–1140PubMedGoogle Scholar
  66. 66.
    Rees RC, McArdle S, Mian S, Li G, Ahmad M, Parkinson R, Ali SA (2002) Disabled infectious single cycle-herpes simplex virus (DISC–HSV) as a vector for immunogene therapy of cancer. Curr Opin Mol Ther 4:49–53PubMedGoogle Scholar
  67. 67.
    Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474–478CrossRefPubMedGoogle Scholar
  68. 68.
    Rojas JM, McArdle SE, Horton RB, Bell M, Mian S, Li G, Ali SA, Rees RC (2005) Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53. Cancer Immunol Immunother 54:243–253CrossRefPubMedGoogle Scholar
  69. 69.
    Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101(Suppl 2):14639–14645CrossRefPubMedGoogle Scholar
  70. 70.
    Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL (1990) Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578PubMedCrossRefGoogle Scholar
  71. 71.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327PubMedGoogle Scholar
  72. 72.
    Ruedl C, Kopf M, Bachmann MF (1999) CD8(+) T cells mediate CD40-independent maturation of dendritic cells in vivo. J Exp Med 189:1875–1884CrossRefPubMedGoogle Scholar
  73. 73.
    Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G (2003) Vaccination with irradiated autologous tumour cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments anti-tumour immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21:624–630CrossRefPubMedGoogle Scholar
  74. 74.
    Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, Friedman SM (1996) CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt’s lymphoma B cells. Blood 88:1375–1382PubMedGoogle Scholar
  75. 75.
    Schirrmacher V (2005) Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54:587–598CrossRefPubMedGoogle Scholar
  76. 76.
    Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature 393:480–483CrossRefPubMedGoogle Scholar
  77. 77.
    Schwartz RH, Mueler DL, Jenkins MK, Quill H (1989) T-cell clonal anergy. Cold Spring Harb Symp Quant Biol 56:605–610Google Scholar
  78. 78.
    Segal BM, Glass DD, Shevach EM (2002) Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 168:1–4PubMedGoogle Scholar
  79. 79.
    Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337–339CrossRefPubMedGoogle Scholar
  80. 80.
    Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT (2004) Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5:1143–1148CrossRefPubMedGoogle Scholar
  81. 81.
    Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G (2003) Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments anti-tumour immunity in patients with metastatic melanoma. J Clin Oncol 21:3343–3350CrossRefPubMedGoogle Scholar
  82. 82.
    Steinaa L, Rasmussen PB, Wegener AM, Sonderbye L, Leach DR, Rygaard J, Mouritsen S, Gautam AM (2005) Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J Immunol 175:329–334PubMedGoogle Scholar
  83. 83.
    Strand S, Hoffmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Gale PR (1996) Lymphocytes apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells: a mechanism of immune evasion. Nat Med 2:1363–1366CrossRefGoogle Scholar
  84. 84.
    Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339–342CrossRefPubMedMathSciNetGoogle Scholar
  85. 85.
    Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M (2006) CD25 expression is correlated with histological grade and response to Denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126(3):575–583CrossRefPubMedGoogle Scholar
  86. 86.
    Tang HL, Cyster JG (1999) Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 284:819–822CrossRefPubMedGoogle Scholar
  87. 87.
    Thomas WD, Hersey P (1998) CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer 75:384–390CrossRefPubMedGoogle Scholar
  88. 88.
    Thomas WD, Hersey P (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 161:2195–2200PubMedGoogle Scholar
  89. 89.
    Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA (1994) Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91:9461–9465PubMedGoogle Scholar
  90. 90.
    Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP (2000) Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol 164:3535–3542PubMedGoogle Scholar
  91. 91.
    Vignard V, Lemercier B, Lim A, Pandolfino MC, Guilloux Y, Khammari A, Rabu C, Echasserieau K, Lang F, Gougeon ML, Dreno B, Jotereau F, Labarriere N (2005) Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol 175:4797–4805PubMedGoogle Scholar
  92. 92.
    Von Boehmer H (2005) Mechanisms of suppression by suppressor T cells. Nat Immunol 6:338–344CrossRefPubMedGoogle Scholar
  93. 93.
    Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044CrossRefPubMedGoogle Scholar
  94. 94.
    Wang RF (2001) The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 22:269–276CrossRefPubMedGoogle Scholar
  95. 95.
    Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J (1999) Phase I trial of a MART-1 peptide vaccine with incomplete Freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res 5:2756–2765PubMedGoogle Scholar
  96. 96.
    Wang RF, Zeng G, Johnston SF, Voo K, Ying H (2002) T cell-mediated immune responses in melanoma: implications for immunotherapy. Crit Rev Oncol Hematol 43:1–11PubMedGoogle Scholar
  97. 97.
    Wang HY, Lee DA, Peng G, Guo G, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumour specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20:107–118CrossRefPubMedGoogle Scholar
  98. 98.
    Wang HY, Peng Y, Guo Z, Shevach EM, Wang RF (2005) Recognition of a new ARCT1 peptide ligand uniquely expressed in tumour cells by antigen-specific CD4+ regulatory T cells. J Immunol 174:2661–2670PubMedGoogle Scholar
  99. 99.
    Wu Y, Liu Y (1994) Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T-cell help in CD8+ T-cell responses. Curr Biol 4:499–505CrossRefPubMedGoogle Scholar
  100. 100.
    Xiang J, Huang H, Liu Y (2005) A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol 174:7497–7505PubMedGoogle Scholar
  101. 101.
    Yamaguchi T, Sakaguchi S (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16(2):115–123CrossRefPubMedGoogle Scholar
  102. 102.
    Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T-cell-mediated CD8 tolerance. Nat Immunol 5(5):508–515CrossRefPubMedGoogle Scholar
  103. 103.
    Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99:16168–16173CrossRefPubMedGoogle Scholar
  104. 104.
    Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ (2000) Melan-A/MART-1(51–73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 97:400–405CrossRefPubMedGoogle Scholar
  105. 105.
    Zhan Y, Corbett AJ, Brady JL, Sutherland RM, Lew AM (2000) CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation. J Immunol 165:3612–3619PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Deepak P. Assudani
    • 1
  • Roger B. V. Horton
    • 1
  • Morgan G. Mathieu
    • 1
  • Stephanie E. B. McArdle
    • 1
  • Robert C. Rees
    • 1
    Email author
  1. 1.School of Biomedical and Natural SciencesNottingham Trent UniversityNottinghamUK

Personalised recommendations